Search results for "RETINA"
showing 10 items of 864 documents
Automated macular choroidal thickness measurement by swept-source optical coherence tomography in pseudoxanthoma elasticum
2016
Introduction Pseudoxanthoma elasticum (PXE) typically involves elastic fibers in blood vessels and Bruch membrane. Our purpose was to analyze retinal and choroidal macular thickness in patients with angioid streaks due PXE compared with a control group. Methods Best-corrected visual acuity (BCVA), axial length (AL), and macular swept-source optical coherence tomography were obtained. Automated segmentations of the retina and the choroid were used to obtain the corresponding thickness values. An age, gender and AL matched control group was used to compare the thickness values. Results Twelve eyes of 6 patients were included. The mean BCVA was 0.68 ± 0.29 versus 1.0 in controls (p < 0.001). T…
High-resolution images in macular disorders
2021
Objective: This study analyzed and compared the results of adaptive optics (AO) and fundus autofluorescence (FAF) in various maculopathies. Methods: The study included four different types of maculopathy: central serous chorioretinopathy (CSC), retinitis pigmentosa (RP), Stargardt disease (STGD) and phototoxic retinopathy. In all four cases, cone mosaic and cone density were obtained using AO fundus camera. Further, the high-resolution images were compared with the FAF and optical coherence tomography (OCT) results. Results: In CSC, FAF and AO, changes could be shown in the macula even two years after the subretinal fluid resorption, as opposed to a normal OCT. The improvement of FAF and co…
Intravitreal Pegaptanib in Ischemic CRVO Refractory Exudative Macular Detachment
2012
Abstract Recent literature data reported evidence of the visual and/or anatomical benefits of all clinically available anti-VEGF drugs for the treatment of macular edema (ME) following Central Retinal Vein Occlusion (CRVO), up to 1-year followup. There are no randomized clinical trial data on anti-VEGF agents in ischemic CRVO-ME and the use of anti-VEGF agents to treat this condition. A 73-year old caucasian man, with a medical history of diabetes and systemic hypertension and an ophthalmic history of ischemic CRVO with cystoid macular edema was referred to our division on January 2011. The ophthalmic examination showed in right eye a visual acuity of 20/2000, a C2N1 cataract and an exudati…
Management of macular edema due to branch retinal vein occlusion with intravitreal injections of pegaptanib sodium
2009
Purpose To evaluate the efficacy of Pegaptanib Sodium as single therapy for macular edema due to non-ischemic branch retinal vein occlusion. Methods In this uncontrolled prospective pilot study 17 patients have been included with non-ischemic branch retinal vein occlusion. All of them showed macular edema in the OCT with central foveal thickness higher than 350 microns (mean, 541 +/- 140) and decrease in visual acuity lower than 0,5 Snellen ETDRS charts notation (mean, 0,16+/-0,14). After an initial injection of Pegaptanib Sodium evaluations were programmed every 5 weeks and further retreatments were developed in cases with macular thickness higher than 300 microns. No other therapies were …
Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic re…
2019
Purpose Panretinal photocoagulation (PRP) is the current standard of care in proliferative diabetic retinopathy (PDR). However, treatment with anti-vascular endothelial growth factor agents might offer better patient outcomes with fewer side-effects. The PRIDE study aimed to assess the efficacy and safety of ranibizumab with or without PRP compared with PRP alone in patients with PDR. Methods A total of 106 PDR patients without diabetic macular oedema were randomized to receive ranibizumab 0.5 mg monotherapy (n = 35), PRP (n = 35) or combined ranibizumab 0.5 mg/PRP (n = 36). The primary objective of this 12-month, multicentre, phase II study was to investigate the change in area of retinal …
Nd:YAG-Laserung einer retrohyaloidalen Blutung nach Venenastverschluss
2006
Background A retrohyaloidal haemorrhage can be caused by different underlying diseases. Usually dense haemorrhages are treated by early vitrectomy. We want to report the successful treatment of a retrohyaloidal haemorrhage by means of Nd:YAG laser membranotomy. Materials and methods A 47-year-old man noticed two weeks before presentation a sudden visual loss in the left eye. Visual acuity on the first visit was c. c. 20/32 OD and c. c. 20/400 ex. OS. Dilated fundus examination of the left eye showed multiple intraretinal haemorrhages in the superior periphery and a dense retrohyaloidal haemorrhage over the macula. Anamnestic risk factors for ocular bleeding were systemic hypertension in con…
Photodynamic Therapy in Subfoveal Choroidal Neovascularisation
2002
Summary The exudative form of age-related macular degeneration (AMD) is the leading cause of blindness among people over 50 years of age in the western world. In 2–10% of cases a subfoveal choroidal neovascularisation develops. Conventional laser treatment leads to an unspecific destruction of the CNV including adjacent retinal structures. In addition, significant and immediate vision loss occurs, particularly in cases with central, subfoveal localization of the CNV.Photodynamic therapy (PDT) employing photochemical activation of verteporfin as a photosensitizer induces selective occlusion of CNV with minimal damage to the neurosensory retina and does not impair visual acuity. It became ava…
Intravitreal Dexamethasone Implant for Postoperative Macular Oedema Secondary to Vitrectomy for Epiretinal Membrane and Retinal Detachment: A Systema…
2021
Purpose. To evaluate the efficacy of intravitreal dexamethasone implant (DEX) for the treatment of macular oedema secondary to vitrectomy for epiretinal membrane (ERM) and retinal detachment (RD) by conducting a systematic review with meta-analysis of published studies. Methods. Studies reporting clinical outcomes of DEX use for the treatment of macular oedema secondary to ERM and RD vitrectomy were searched on PubMed and Embase databases. The primary outcome was best-corrected visual acuity (BCVA) change between baseline and post-DEX treatment, reported as mean difference (MD) with 95% confidence interval (CI). Mean central macular thickness (CMT) change was assessed as a secondary outcome…
Seasonal Variations on the Cortisol Concentration of the Subretinal Fluid in Rhegmatogenous Retinal Detachment
1981
Probes of the subretinal fluid were obtained from 115 nonselected retinal detachments, operated on during the period from November 19, 1973 to December 20, 1974. All patients had no known endocrine abnormalities and had not ever received topical or systemic corticosteroid therapy. Subretinal fluid Cortisol was determined by competitive protein binding analysis. A statistically significant increase in mean subretinal fluid Cortisol concentration was found for the winter season (3.3 µg/100 ml), as compared with the summer months (1.5 µg/100 ml). This finding sharply contrasts with the seasonal incidence of the idiopathic retinal detachments which reaches its maximum in the months June to Augu…